- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis
December 12th 2021, 8:39pm
ASH Annual Meeting and Exposition
The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.
MRD-Guided Therapy Could Inform Treatment-Free Surveillance in Newly Diagnosed Multiple Myeloma
December 12th 2021, 8:08pm
ASH Annual Meeting and Exposition
Minimal residual disease, assessed through next-generation sequencing was found to inform treatment selection and duration with daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant in patients with newly diagnosed multiple myeloma.
Axi-Cel Improves QoL in Second-Line Treatment of LBCL
December 12th 2021, 7:02pm
ASH Annual Meeting and Exposition
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.
Weekly Selinexor/Bortezomib/Dexamethasone Combo Demonstrates Favorable Efficacy and Safety in High-Risk Multiple Myeloma
December 12th 2021, 6:33pm
ASH Annual Meeting and Exposition
Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.
Chemotherapy Plus Eryaspase Demonstrates Efficacy in ALL With Risk for Hypersensitivity Reactions
December 12th 2021, 6:29pm
ASH Annual Meeting and Exposition
The addition of eryaspase to chemotherapy demonstrated biological efficacy and tolerability in patients with acute lymphoblastic leukemia who are at risk of developing hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.
Tisagenlecleucel Continues to Show Favorable Real-World Efficacy and Safety in R/R B-Cell Non-Hodgkin Lymphomas
December 12th 2021, 6:18pm
ASH Annual Meeting and Exposition
Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.
Asciminib Induces Deeper and Prolonged Molecular Responses in Chronic-Phase CML
December 12th 2021, 6:06pm
ASH Annual Meeting and Exposition
Asciminib demonstrated a consistent improvement in major molecular response rate and depth of response vs bosutinib in patients with chronic-phase chronic myeloid leukemia without any new or worsening adverse effects.
Ibrutinib Plus R-Mini-CHOP Misses OS End Point but Shows Improved PFS in Newly Diagnosed DLBCL
December 12th 2021, 5:52pm
ASH Annual Meeting and Exposition
Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma.
Acalabrutinib Provides Long-Term Survival Benefits Vs. Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia
December 12th 2021, 5:32pm
ASH Annual Meeting and Exposition
Treatment with acalabrutinib for relapsed/refractory chronic lymphocytic leukemia was effective out to 3 years and demonstrated a progression-free survival benefit over standard of care, according to 3-year follow-up of the ASCEND study.
Frontline and Continuous Treatment With Ibrutinib Plus Rituximab Improves Quality of Life in Patients With CLL
December 12th 2021, 5:25pm
ASH Annual Meeting and Exposition
Quality of life improved in patients with chronic lymphocytic leukemia when treated in the frontline setting with ibrutinib-rituximab and with fludarabine, cyclophosphamide, and rituximab. Improved quality of life was also maintained during continuous therapy with ibrutinib and did not decline over time.
Real-World Efficacy of Tisagenlecleucel in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Similar to Clinical Trial Data With Improved Safety Outcomes
December 12th 2021, 4:58pm
ASH Annual Meeting and Exposition
Real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with tisagenlecleucel demonstrated similar efficacy outcomes and a more favorable safety profile compared with the ELIANA trial.
Selinexor Plus D-Vd Shows Promising Results and Safety in Patients With Relapsed or Refractory Multiple Myeloma
December 12th 2021, 4:50pm
ASH Annual Meeting and Exposition
Selinexor in combination with daratumumab, bortezomib and dexamethasone demonstrated a manageable safety profile and encouraging efficacy in patients with late- and early-relapsed multiple myeloma.
Ponatinib Elicits Encouraging Activity in TKI-Resistant CP-CML
December 12th 2021, 1:55pm
ASH Annual Meeting and Exposition
Ponatinib demonstrated high response rates in patients with TKI-resistant, chronic-phase chronic myeloid leukemia, irrespective of T315I mutation status at baseline, according to findings from the phase 2 OPTIC trial.
Depression, Anxiety Affect Patient Perceptions of Cancer Clinical Trials
December 12th 2021, 1:43pm
ASH Annual Meeting and Exposition
Depression and anxiety can play a significant role in how patients with cancer view cancer clinical trials, ultimately leading to low enrollment
Active Disease, ICU Deferral Linked With COVID-19–Related Mortality in AML, ALL, and MDS
December 12th 2021, 12:08am
ASH Annual Meeting and Exposition
Mortality rates in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome who were diagnosed with COVID-19 were higher compared with non-cancer populations who were infected with the virus.
Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL
December 11th 2021, 11:53pm
ASH Annual Meeting and Exposition
The combination of tafasitamab and lenalidomide prolonged median overall survival compared with other standard options for autologous stem cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
Loncastuximab Tesirine/Ibrutinib Combination Elicits Encouraging Activity in Relapsed/Refractory DLBCL
December 11th 2021, 11:04pm
ASH Annual Meeting and Exposition
Treatment with ibrutinib plus loncastuximab tesirine-lpyl resulted in high objective and complete response rates and an acceptable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from an interim analysis of the phase 1/2 LOTIS-3 trial (NCT03684694) that were presented at the 2021 ASH Annual Meeting and Exposition.
Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin Lymphoma
December 11th 2021, 11:04pm
ASH Annual Meeting and Exposition
Sattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Strong Antibody Response to mRNA COVID-19 Vaccine Observed in AML, MDS
December 11th 2021, 10:50pm
ASH Annual Meeting and Exposition
An observational single-center study suggests that mRNA-1273 SARS CoV-2 vaccination induces a strong antibody response in patients with acute myeloid leukemia and myelodysplastic syndrome, according to observational results presented during the 2021 ASH Annual Meeting.
Daratumumab Plus VTd Enhances MRD-Negativity Rates in Transplant-Eligible Myeloma
December 11th 2021, 10:47pm
ASH Annual Meeting and Exposition
Minimal residual disease–negativity rates were significantly higher after utilizing daratumumab plus bortezomib, thalidomide, and dexamethasone (VTd) vs VTd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the phase 3 CASSIOPEIA study that were presented at the 2021 ASH Annual Meeting and Exposition.